Hadassah

Hadassah Conducts Unprecedented Trial of Stem Cell Treatment for MS

Thursday, Jun 25 2015

Prof. Dimitrios Karussis, head of Hadassah Medical Organization’s Multiple Sclerosis Center

An unprecedented clinical trial launched at the Hadassah Medical Organization, which will test the effectiveness of a treatment for Multiple Sclerosis (MS) involving multiple injections of enhanced stem cells directly into the cerebrospinal fluid, could bring hope to the 2.5 million patients worldwide suffering from this neurodegenerative disease.

The trial, under the direction of Prof. Dimitrios Karussis, head of Hadassah’s Multiple Sclerosis Center, is a large randomized double-blind, placebo-controlled study that will eventually have 48 MS patients. While the patients in the control group will not know if they are initially getting the actual treatment or a placebo, the trial contains a crossover design so that eventually everyone will get the stem cell treatment, although some patients will receive the actual treatment six months later.

The novel concept of injecting the stem cells directly into the spinal fluid is aimed at getting the cells to circulate to the various damaged areas of the central nervous system. The injected stem cells, explains Prof. Karussis, “are at their preliminary stage of maturity,”  having the potential to renew the damaged myelin, the nerve covering that degenerates in MS, as well as to suppress the disease. “The cell renewal process,” he says, “will not only prevent future MS attacks, but will also significantly improve motor and cognitive functions which were previously affected by MS, including walking, memory, and more. Preliminary results of our trial have seen wheelchair-bound patients getting back on their own two feet.”

Prof. Karussis hopes to have an interim analysis of the results within one year; the study is intended to be completed at the end of 2016 or early 2017.

“This is truly a groundbreaking trial on a worldwide scale,” concludes Prof. Karussis. “The various unprecedented components of the trial, including the multiple subjects, unique injection technique, and double-injection hope to pave the way to a new form of treatment for MS.”

Comments

From: Steve on August 13, 2016
I am interested in stem cell therapy. I have Lupus which caused stage 4 non-alcoholic liver cirrhosis. Just had my fibroscan and test was 26.7 Can you lead me to the right direction.
From: Rick on October 28, 2015
I was diagnosed with primary progressive MS in 1998 at the age of 54. I will be in Israel for the next few weeks and would like to be considered for treatment. I am currently being seen at the MS facility at UTSW in Dallas.
From: Sydney on September 26, 2015
Hello -- My 64-year-old brother-in-law with relapsing-remitting MS has asked me to contact you regarding your new trials injecting stem cells into the cerebrospinal fluid of MS patients. He is very hopeful about your research and would like to receive the treatment. Please advise. He lives in the United States but would be willing to travel to Israel for the treatment.
From: Phoebe on August 18, 2015
I have peripheral neuropathy caused by one of the chemos used to treat me for non-Hodgkins Lymphoma. I was diagnosed in 1999, being in stage 3. After a stem cell transplant in 2000, I have been in remission. The neuropathy has been progressive & while it began in the tip of one toe, it now encompasses both legs to above the knees. Would I be considered a good candidate for this reatment
From: Elizabeth on August 6, 2015
I wish I could participate in this study. I have relapsing-remitting MS.
From: Gloria on August 6, 2015
Stupid autocorrect. Relapsing-remitting
From: Gloria on August 6, 2015
Meant to say relapsing-unremitting MS
From: Gloria on August 6, 2015
I have relapsing-unremitting MS diagnosed in 1991' I'm excited to hear about the results of this study.
From: Aileen on August 5, 2015
Could this treatment possibly help those with idiopathic peripheral neuropathy?
From: Nancy Ullman on August 2, 2015
Please may I participate in this study...I have secondary progressive and will travel anywhere to receive this treatment.
From: Pearl on July 23, 2015
I am a member of the Society of Major Donors. I have a niece who is a nurse & has MS. How can she get involved in this study? Is there any way we can help her so she can continue to help others?
From: Monique on July 13, 2015
Hi, I have primary progressive MS. I would like to know the possibilities of participating in this study or similar Intrathecal stem cell study. Thank you,
From: George on July 7, 2015
What do i need to do to become a part of this study please let me know what the situation is with the study.
From: Dotty on July 6, 2015
How do you become part of this study? I would be interested.
From: franca on July 1, 2015
Hi, my name is franca Cocuzza . I have secondary progressive ms. Could I participate in this study? Please let me know.
From: Anonymous on July 1, 2015
Hi, my name is franca Cocuzza . I have secondary progressive ms. Could I participate in this study? Please let me know.
From: Stuart on June 30, 2015
This article now shared with tens of thousands of MS patients: http://wwwmsviewsandrelatednews.blogspot.com/2015/06/hadassah-conducts-unprecedented-trial.html thank you!
From: EVie on June 30, 2015
THought you would want to see this
From: mike sherbin on June 30, 2015
THought you would want to see this. Evie
From: Harriet on June 30, 2015
Would love to know specifically on which type of MS this study is being performed. How can I become a participant? Live in U.S.
First Name
Email
Comment
Enter this word:

Related Stories

alt_text

Wednesday, Nov 30 2016

Hadassah Teams Up with Spinal Cord Institute to Study Outcomes of Traumatic Injuries

The medical interventions and outcomes for Israelis with a spinal cord injury (SCI) will now be captured in the Rick Hansen SCI Registry (RHSCIR), thanks to the November 16th launch of a partnership between the Hadassah Medical Organization and the Rick Hansen Institute (RHI), a Canadian-based not-for-profit organization named after the paralympic athlete who suffered a severe spinal cord injury following a car accident.

READ MORE ›
alt_text

Thursday, Nov 17 2016

A Birthday Party in Hadassah’s PICU: Helping a Four-Year-Old Recover

Yehoshua "Shuki" Pepper was crossing a Jerusalem street with an older sibling when a car ran him over. He was rushed to Hadassah Hospital Ein Kerem's Pediatric Intensive Care Unit in fair condition, but he wasn't speaking and subsequent MRIs of his head injury were worrisome.

READ MORE ›
alt_text

Thursday, Nov 17 2016

Ethiopian Pre-Nursing Students: On the Way to Fulfilling a Dream

“I know that some people are fine with looking at a screen all day, but I know I need the human touch--to work with people. I want to be a nurse, " relates Sarah Talala, one of the 18 students of Ethiopian background who were given the opportunity to take a course which enabled them to advance to pre-academic studies at the Hebrew University and then on to nursing school at the Hadassah-Hebrew University Henrietta Szold School of Nursing.

READ MORE ›
alt_text

Monday, Nov 14 2016

Granalix BioTechnologies Introduces Food Additive to Protect Against Neurodegenerative Disease

Granalix BioTechnologies, whose founder and Chief Executive Officer is Hadassah Medical Organization Experimental Neurologist Prof. Ruth Gabizon, has launched a food supplement containing pomegranate oil that has proven to protect against neurodegenerative diseases in pre-clinical models.

READ MORE ›

Contact Us

40 Wall Street

New York, NY 10005

support@hadassah.org

More ›

Membership Questions

membership@hadassah.org

(800) 664-5646

Donation Questions

donorservices@hadassah.org

(800) 928-0685

Missions Department

missions@hadassah.org

(800) 237-1517

Show More